Tipp

CDK4/6 inhibition in luminal breast cancer

Zeitschrift:: memo - Magazine of European Medical Oncology > Ausgabe 2/2016

Autoren:: Simon Peter Gampenrieder, Gabriel Rinnerthaler, Richard Greil

» Zum Volltext PDF-Version jetzt herunterladen

Wichtige Hinweise

Authors’ contributions. All authors: data analysis and interpretation, final approval of manuscript; S. P. Gampenrieder: conception and design, collection and assembly of data, Manuscript writing; G. Rinnerthaler: manuscript writing, critical revising of the manuscript, critical revising of the manuscript; R. Greil: critical revising of the manuscript

Summary

Endocrine therapy represents the basis for the treatment of estrogen receptor-positive breast cancer, but several tumors harbor intrinsic resistance and acquired resistance to endocrine therapy is inevitable in metastatic disease. Combination strategies of endocrine therapy with targeted agents are aimed to overcome endocrine resistance. The selective CDK4/6 inhibitor palbociclib has shown promising results in metastatic luminal breast cancer when used in combination with endocrine therapy both in the first-line setting as in pretreated women. The drug showed a manageable safety profile with uncomplicated neutropenia as the most frequent side effect. Approval was already granted in the US and is also awaited during 2016 for Europe.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. CrossRefPubMed

Cancer Genome Atlas. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. CrossRef

Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol. 2011;137(10):1409–18. CrossRefPubMed

Finn RS, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35. CrossRefPubMed

Turner NC, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209–19. CrossRefPubMed

Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer. 2008;8(9):714–24. CrossRefPubMedPubMedCentral

Asghar U, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–46. CrossRefPubMedPubMedCentral

Witkiewicz AK, Knudsen ES. Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Res. 2014;16(3):207. CrossRefPubMedPubMedCentral

Lange CA, Yee D. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer. 2011;18(4):C19–24. CrossRefPubMedPubMedCentral

10.

Ma CX, et al. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer. 2015;15(5):261–75. CrossRefPubMed

11.

Finn RS, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. CrossRefPubMedPubMedCentral

12.

Dean JL, et al. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010;29(28):4018–32. CrossRefPubMed

13.

DeMichele A, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015;21(5):995–1001. CrossRefPubMed

14.

Malumbres M, et al. Mammalian cells cycle without the D‑type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 2004;118(4):493–504. CrossRefPubMed

15.

Hu W, et al. Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies. Clin Cancer Res. 2015;22(8):2000–8. CrossRefPubMed

16.

Herrera-Abreu MM. et al. PI3 kinase/mTOR inhibition increases sensitivity of ER positive breast cancers to CDK4/6 inhibition by blocking cell cycle re-entry driven by cyclinD1 and inducing apoptosis. IMPAKT Meeting. 2015, abstr. 86O.

17.

Wang L, et al. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood. 2007;110(6):2075–83. CrossRefPubMed

18.

Lenihan C, et al. Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer. Cancer Res. 2015;76(4 Supplement):P3-06-02 doi:10.1158/1538-7445.SABCS15-P3-06-02. CrossRef

19.

Vora SR, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 2014;26(1):136–49. CrossRefPubMedPubMedCentral

20.

Kim S. et al. LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6 – Reactivating Rb in cancer. AACR-NCI-EORTC. 2013, abstr. B264.

Titel: CDK4/6 inhibition in luminal breast cancer
Autoren:: Simon Peter Gampenrieder
Gabriel Rinnerthaler
Richard Greil
Publikationsdatum: 01.06.2016
DOI: https://doi.org/10.1007/s12254-016-0268-2
Verlag: Springer Vienna
Zeitschrift: memo - Magazine of European Medical Oncology An International Journal for Oncology and Haematology Professionals
Ausgabe 2/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Weitere Artikel der Ausgabe 2/2016

Initial emergencies in children and adolescents with malignant hematologic–oncological diseases

Circulating tumor cells and circulating tumor DNA in colon cancer

Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer

Endometrial cancer treated with levonorgestrel-releasing intrauterine device for almost three years in an elderly woman with comorbidity

Is there room for chemotherapy in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) in the era of targeted hormone therapy?

Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option